Please type a plus sign (+) inside this box	1
Please type a plus sign (+) inside this box	T .

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known			
	 :			Application Number	09/889,227	
				Filing Date	July 12, 2001	
STA	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	First Named Inventor	Bernd Riedl et al.			
				Group Art Unit	1625	
	(use as mar	ny sheets as	necessary)	Examiner Name	Rita Desai	
Sheet	1	of	5	Attorney Docket Number	BAYER 15A	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
R	AA	A "Notice of References Cited" from the USPTO for U.S. application 08/995,749, filing date of 12/2/98, Inhibition Of P38 Kinase Using Symmetrical And Unsymmetrical Diphenyl Ureas .	
p	AB	A "Notice of References Cited" from the USPTO for U.S. application 09/083,399, filing date of 1/8/01, Inhibition of Raf Kinase Activity Using Aryl Ureas.	
b	AC AND AD	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228, filing date of 9/10/01, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS.	
p	AE	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229, filing date of 3/4/02, OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS.	
p	AF	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015, filing date of 2/1/02, INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS.	
PO	AG	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas.	
P	АН	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas.	
P	AI	A "Notice of References Cited" from the USPTO for U.S. application 09/773,604, filing date of 2/2/01, Publication No. US 2001-0034447-A1, Publication Date 10/25/01, Omega-carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors.	
po	AJ	A "Notice of References Cited" from the USPTO for U.S. application 09/773,659, filing date of 2/2/01, W-carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors.	
RO	AK	A "Notice of References Cited" from the USPTO for U.S. application 09/773,672, filing date of 2/2/01, Publication No.: US 2001-0016659 A1, Publication Date: August 23, 2001, Omega-carboxyaryl substituted Diphenyl Ureas as Raf Kinase Inhibitors.	
P	AL	A "Notice of References Cited" from the USPTO for U.S. application 09/773,675, filing date of 2/2/01, Publication No.: US 2001-0011136-A1, Publication Date: August 2, 2001, Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors.	

Examiner Signature	Dera	Date Considered	10/08/04
1 - 3	11	B .	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO 09/889,227 **Application Number** INFORMATION DISCLOSURE Filing Date July 12, 2001 STATEMENT BY APPLICANT Bernd Riedl et al. First Named Inventor **Group Art Unit** 1625 (use as many sheets as necessary) **Examiner Name** Rita Desai BAYER 15A Attorney Docket Number Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
Ro	AM	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935 filing date of 12/22/98, Inhibition Of P38 Kinase Using ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC Ureas	
p	AN	A "Notice of References Cited" from the USPTO for U.S. application 09/776,936, filing date of 12/22/98, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS.	
p	AO	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920, filing date of 2/7/02, OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS.	
P	АР	A "Notice of References Cited" from the USPTO for U.S. application 09/948,915, filing date of 2/11/02, OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS.	
R	ΑQ	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226, filing date of 1/1/02, OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS.	
ps	AR	Supplemental search report from the EPO for European application EP 98/963809 dated 3/30/01, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS, publication No. 1049664, publication date 11/8/2000.	
RO	AS	Supplemental search report from the EPO for European application EP 98/963810 dated 12/21/00, INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS, publication No. 1056725, publication date 12/6/2000.	
Ro	АТ	Supplemental search report from the EPO for European application EP 98/965981 dated 12/21/00, INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS, publication No. 1047418, publication date 11/2/2000.	
RO	AU	Supplemental search report from the EPO for European application EP 00/903239 dated 8/7/02, OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS.	
po	ВА	International search report for International Application No. PCT/US98/10375 dated 9/3/98, INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS, publication No. 98/52558, publication date11/26/1998.	
Ro	88	International search report for International Application No. PCT/US98/10376 dated 7/30/98, RAF KINASE INHIBITORS, publication No. WO 98/52559, publication date 11/26/1998.	

1.1020	Date Considered	10/08/04
--------	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.dot

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO Application Number 09/889,227 INFORMATION DISCLOSURE July 12, 2001 Filing Date STATEMENT BY APPLICANT Bernd Riedl et al. First Named Inventor Group Art Unit 1625 (use as many sheets as necessary) Examiner Name Rita Desai **BAYER 15A** Attorney Docket Number Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RO	вс	International search report for International Application No. PCT/US98/26078 dated 4/2/99, INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS, publication no. WO99/32106, publication date 7/1/1999	
Ro	BD	International search report for International Application No. PCT/US98/26079 dated 4/12/99, INHIBITION OF p38 ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS, publication No. WO99/32110, publication date7/1/1999	
Ro	BE	International search report for International Application No. PCT/US98/26080 dated 4/12/99, INHIBITION OF p38 KINASE USING SUBSTITUTED HETEROCYCLIC UREAS, publication No. WO99/32111, publication date 7/1/1999	
Ro	BF	International search report for International Application No. PCT/US98/26081 dated 4/2/99, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS, publication No. WO99/32436, publication date7/1/1999.	
RO	BG	International search report for International Application No. PCT/US98/26082 dated 5/12/99, INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS, publication No. WO99/32455, publication date 7/1/1999.	
ps	вн	International search report for International Application No. PCT/US98/24765 dated 3/2/99, , Inhibition Of P38 Kinase Using ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC Ureas.	
Ro	BI	International search report for International Application No. PCT/US00/00648 dated 6/29/00, Omega-Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase Inhibitors.	
PO	ВЈ	International search report for International Application No. PCT/US00/00768 dated 5/16/00, OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS.	
Ro	вк	International search report for International Application No. PCT/US02/12064 dated 9/20/02, OMEGA-CARBOXYPYRIDYL SUBSTITUTED DEPHENYL UREAS AS RAF KINASE INHIBITORS, publication No. 02/085859, publication date 10/31/2002	
pao	BL	International search report for International Application No. PCT/US02/12066 dated 9/13/02, INHIBITION OF RAF KINASE QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS, publication No. 02/085857, publication date10/31/2002.	
PO	ВМ	International search report for International Application No. PCT/US/26081 dated 4/2/99, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS, publication No. WO99/32436, publication date7/1/1999	

Examiner Signature	Roesar	Date Considered	10/8/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.dot

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO Application Number 09/889,227 INFORMATION DISCLOSURE July 12, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Bernd Riedl et al. 1625 **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Rita Desai Attorney Docket Number **BAYER 15A** Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
RO	ΚΥ	Scott, Bill, "Substructure Search", December 2, 1997, pages 1-51.	
PP	KZ	"Beilstein Number" Collection, 28 pages (1997)	
RO	LA	"Beilstein Collection:, 4 pages (1997)	· · ·
P	LB	Scott, Bill, "Substructure Search", December 2, 1997, pages 1-51	
RA	LC	Substructure Search, pages 1-30 (1997)	
ps	LD	Derwent World Patents Index Search, pages 20-26 (1997)	

<u></u>			

Examiner Riberar	Date Considered	10/8/04]
------------------	--------------------	---------	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.dot

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Sheet

of 5

Approved for use through 10/31/2002. OMB 0551-0031*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

BAYER 15A

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number

Substitute for form 1449A/PTO

Application Number 09/889,227

INFORMATION DISCLOSURE Filing Date July 12, 2001

STATEMENT BY APPLICANT First Named Inventor Bernd Riedl et al.

Group Art Unit 1625

(use as many sheets as necessary)

Examiner Name Rita J. Desai

	U.S. PATENT DOCUMENTS									
Examiner Initials		U.S. Patent Document			Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant			
	Cite No.1	Number	Kind C (if kno		of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
	ļ	ļ	,							
	ļ									
	 . 	 								
	 	 			··· - · · - · · - · · · · · · · · · · ·					
	 	 								
						7.				
		<u> </u>								
		<u> </u>								
		 								
					<u> </u>					
.		<u> </u>								
		 								

	FOREIGN PATENT DOCUMENTS										
Examiner Cite		Fo	reign Patent Do	cument	Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant				
Initials*	No. ¹	Office	Number⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T _B			
RD	ВО	IR	26555		•	7-17-00					
po	BP	LB	6124			5-4-00					
	ļ <u>.</u>				- ,						
				- 							
	<u> </u>										
				_							
		ļ									

Examiner Signature Date Considered $0/8/3$	04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.